Effects of medications on post-endoscopic retrograde cholangiopancreatography pancreatitis

Pancreatology

Volumn 10, Issue 2-3, 2010, Pages 238-242

  Li, N ^a   Tieng, A ^a   Novak, S ^a   Fernandes, A ^a   Jalal, P K ^a   Akerman, M ^b   Sideridis, K ^a   Bank, S ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Angiotensin receptor blocker; Endoscopic retrograde cholangiopancreatography; Pancreatitis; Propofol; Smoking

Indexed keywords

MIDAZOLAM; PROPOFOL; ANGIOTENSIN RECEPTOR ANTAGONIST; FENTANYL; HYPNOTIC SEDATIVE AGENT;

ARTICLE; CIGARETTE SMOKING; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; ADOLESCENT; ADULT; AGED; CHEMICALLY INDUCED; MIDDLE AGED; RISK FACTOR; SMOKING; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; FEMALE; FENTANYL; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDAZOLAM; MIDDLE AGED; PANCREATITIS; PROPOFOL; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 77952316826     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000279306     Document Type: Article

References (27)

1. Trivedi CD, Pitchumoni CS: Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39: 709-716.
2. Gottschling S, Larsen R, Meyer S, et al: Acute pancreatitis induced by short-term propofol administration. Paediatr Anaesth 2005; 15: 1006-1008.
3. Jawaid Q, Presti ME, Neuschwander-Tetri BA, et al: Acute pancreatitis after single-dose exposure to propofol: a case report and review of literature. Dig Dis Sci 2002; 47: 614- 618.
4. Kumar AN, Schwartz DE, Lim KG: Propofolinduced pancreatitis: recurrence of pancreatitis after rechallenge. Chest 1999; 115: 1198-1199.
5. Cheng CL, Sherman S, Watkins JL, et al: Risk Factors for Post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101: 139-147.
6. Gershon T, Olshaker JS: Acute pancreatitis following lisinopril rechallenge. Am J Emerg Med 1998; 16: 523-524.
7. Maringhini A, Termini A, Patti R, et al: Enalapril- associated acute pancreatitis: recurrence after rechallenge. Am J Gastroenterol 1997; 92: 166-167.
8. Bedrossian S, Vahid B: A case of fatal necrotizing pancreatitis: complication of hydrochlorothiazide and lisinopril therapy. Dig Dis Sci 2007; 52: 558-560.
9. Blomgren KB, Sundström A, Steineck G, Wiholm BE: Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes Care 2002; 25: 298-302.
10. Cotton PB, Lehman G, Vennes J, et al: Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393.
11. Marik PE: Propofol: therapeutic indications and side-effects. Curr Pharm Des 2004; 10: 3639-3649.
12. Farmer RG, Winkelman EI, Brown HB, et al: Hyperlipoproteinemia and pancreatitis. Am J Med 1973; 54: 161-165.
13. Toskes PP: Is there a relationship between hypertriglyceridemia and development of alcohol- or gallstone-induced pancreatitis? Gastroenterology 1994; 106: 810-812.
14. Piper SN, Kumle B, Maleck WH, et al: Effects of postoperative sedation with propofol and midazolam on function assessed by pancreatitis- associated protein. Anaesthesia 2001; 56: 836-840.
15. Gottschling S, Meyer S, Krenn T, et al: Effects of short-term propofol administration on enzymes and triglyceride levels in children. Anaesthesia 2005; 60: 660-663.
16. Devlin JW, Lau AK, Tanios MA: Propofolassociated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy 2005; 25: 1348-1352.
17. Christensen M, Matzen P, Schulze S, et al: Complications of ERCP: a prospective study. Gastrointest Endosc 2004; 60: 721-731.
18. Loperfido S, Angelini G, Benedetti G, et al: Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10.
19. Cheng RM, Mamdani M, Jackevicius CA, et al: Association between ACE inhibitors and acute pancreatitis in the elderly. Ann Pharmacother 2003; 37: 994-998.
20. Birck R, Keim V, Fiedler F, et al: Pancreatitis after losartan. Lancet 1998; 351: 1178.
21. Fisher AA, Bassett ML: Acute pancreatitis associated with angiotensin II receptor antagonists. Ann Pharmacother 2002; 36: 1883-1886.
22. Yamada T, Kuno A, Masuda K, et al: Candesartan, an angiotensin II receptor antagonist, suppresses inflammation and fibrosis in rats. J Pharmacol Exp Ther 2003; 307: 17-23.
23. Yamada T, Kuno A, Ogawa K, et al: Combination therapy with an angiotensin-converting enzyme inhibitor and an angiotensin II receptor blocker synergistically suppresses chronic pancreatitis in rats. J Pharmacol Exp Ther 2005; 313: 36-45.
24. Fimognari FL, Corsonello A, Pastorell R, et al: Metformin-induced pancreatitis: a possible adverse drug effect during acute renal failure. Diabetes Care 2006; 29: 1183.
25. Elmunzer BJ, Waljee AK, Elta GH, et al: A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008; 57: 1262-1267.
26. Lankisch PG: Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 2008; 103: 244.
27. Prat F, Amaris J, Ducot B, et al: Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56: 202-208.